INSIDE INFORMATION: Bioretec updates its product pipeline to accelerate commercialization strategy following the first RemeOs™ FDA market authorization, and consequently updates financial targets
Bioretec Ltd Inside information 24 April 2023 at 1.15 p.m. EESTBioretec Ltd, a pioneer in bioabsorbable orthopedic implants, announced on 30 March 2023 that it had received U.S. market authorization for its RemeOs™ trauma screw from the U.S. Food and Drug Administration (FDA). Following the market authorization, the Board of Directors of Bioretec has today resolved to update and refocus the company's product portfolio to facilitate an accelerated commercialization strategy to provide a more synergistic offering responding to the market demand. Furthermore, Bioretec refines its U.S. go-to-